Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study

University Hospital, Strasbourg, France65 enrolled

Overview

Failure of Weaning from ECMO is a serious complication, reaching an incidence between 29 and 58%. Inotrops are frequently used to help separating patient from ECMO. Levosimendan is an ino-dilatatory medication and was used in different clinical settings. The aim of this study was to evaluate the benefit with levosimendan when used in weaning process.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cardiogenic Shock

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age over 18 * Patient requiring the need for short-term assistance * Patient who has agreed to use his medical data for research purposes Exclusion Criteria: * Refusal to participate in the study * Non-weaning attempts due to a death under assistance or a relay by a long-term assistance or heart transplant * Non-cardiac indications of assistance (indication of pulmonary replacement) * Subject under guardianship or curatorship

Locations (1)

Service Réanimation chirurgicale cardiovasculaire-NHC

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Comparison of the incidence of weaning failure between patients with levosimendan and others

Time frame: Data were recorded from admission until 48 hours after weaning from ECMO

Central Contacts

Gharib AJOB, MD

CONTACT

33 3 69 55 15 70 gharib.ajob@chru-strasbourg.fr

Guillaume HAFFNER, MD

CONTACT

33 3 69 55 15 70 guillaume.haffner@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.